Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,776.00
Bid: 1,775.50
Ask: 1,776.00
Change: -2.00 (-0.11%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Lloyds beats forecasts but markets fall ahead of long weekend

Fri, 01st May 2015 09:05

London stocks fell on Friday despite a better-than-expected first quarter from Lloyds Banking Group as investors were treading carefully in the absence of trading across Europe.The FTSE 100 was down 0.51% at 6,924.94 early on, with most equity markets on the continent closed for May Day.Analyst Craig Erlam from Oanda said the lower open may signal some profit taking and risk aversion ahead of the bank holiday weekend with UK markets closed on Monday."A lot could happen between now and Tuesday with talks continuing between Greece and its creditors and that makes investors quite nervous," he said.In economic data, the official Chinese manufacturing purchasing managers' index (PMI) remained flat at 50.1 in April, slightly ahead of the decline to 50 expected. The non-manufacturing PMI inched higher to 53.4 from 53.7.The UK manufacturing PMI due out at 09:30 is forecast to rise to 54.6 in April from 54.4 in March. Other data released on Friday morning is expected to show an improvement in UK mortgage approvals and UK consumer credit.The closely-watched ISM US manufacturing index is also predicted to rise from 51.5 to 52 in April when it is released at 15:00.Lloyds impressesLloyds Banking Group impressed after delivering a bigger-than-forecast 21% jump in underlying profits in the first quarter as impairment charges more than halved. The UK lender also lifted its net interest margin guidance for the full year and improved its capital position.However, sector peer Barclays was extending losses after disappointing on Wednesday with its own results. Berenberg lowered its rating on the stock to 'sell' on Friday.Mining stocks were mostly higher with Rio Tinto, Anglo American, BHP Billiton, Glencore and Antofagasta all making gains.Glaxosmithkline declined despite its Breo once-daily treatment for adult asthma being approved by the US Food and Drug Administration. The use of Breo in children aged 12-17 was not approved, however.Molten metal flow engineering company Vesuvius fell on the news that its chief financial officer Chris O'Shea is leaving to join technology outfit Smiths Group as its new finance director.Climate control and ventilation systems outfit Colt Group declined after reporting weaker revenues in the first quarter after exiting its low-margin voice services business.Market MoverstechMARK 3,169.82 -0.53%FTSE 100 6,924.94 -0.51%FTSE 250 17,387.51 -0.50%FTSE 100 - RisersLloyds Banking Group (LLOY) 79.76p +3.08%Anglo American (AAL) 1,137.00p +2.90%Rio Tinto (RIO) 2,961.50p +2.65%BHP Billiton (BLT) 1,589.50p +1.83%Antofagasta (ANTO) 793.00p +1.47%Admiral Group (ADM) 1,575.00p +1.09%Weir Group (WEIR) 1,900.00p +1.06%Glencore (GLEN) 313.20p +0.95%Reed Elsevier (REL) 1,090.00p +0.74%Tesco (TSCO) 222.30p +0.59%FTSE 100 - Fallers3i Group (III) 492.40p -2.78%United Utilities Group (UU.) 948.00p -2.37%Barratt Developments (BDEV) 508.50p -2.12%Aberdeen Asset Management (ADN) 465.30p -2.06%Old Mutual (OML) 230.30p -1.96%TUI AG Reg Shs (DI) (TUI) 1,200.00p -1.88%Persimmon (PSN) 1,668.00p -1.88%Royal Mail (RMG) 459.00p -1.86%Hargreaves Lansdown (HL.) 1,209.00p -1.71%Carnival (CCL) 2,939.00p -1.67%FTSE 250 - RisersVedanta Resources (VED) 648.50p +3.18%Ophir Energy (OPHR) 145.20p +2.25%esure Group (ESUR) 223.10p +2.25%Tullow Oil (TLW) 421.80p +1.91%Evraz (EVR) 193.00p +1.74%Cairn Energy (CNE) 181.40p +1.68%Virgin Money Holdings (UK) (VM.) 400.60p +1.62%Premier Oil (PMO) 178.20p +1.60%IP Group (IPO) 199.80p +1.42%Rentokil Initial (RTO) 136.10p +1.34%FTSE 250 - FallersCrest Nicholson Holdings (CRST) 431.60p -3.79%PayPoint (PAY) 826.50p -2.99%Dignity (DTY) 1,978.00p -2.56%Just Retirement Group (JRG) 169.80p -2.41%Diploma (DPLM) 776.00p -2.39%Hellermanntyton Group (HTY) 336.80p -2.38%Bellway (BWY) 1,945.00p -2.36%Genus (GNS) 1,317.00p -2.23%Berendsen (BRSN) 1,016.00p -2.12%Infinis Energy (INFI) 185.60p -2.11%
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.